[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_98":99},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","jbblwk2rg0qi5jm8sz6n4l3ny","revision",2,"title","ADC Therapeutics SA 提交 Form S-4，拟将注册地迁至特拉华州并更名","originalTitle","ADC Therapeutics SA (0001771910) (Filer)","summary","ADC Therapeutics SA 于 2026 年 11 月 3 日提交 Form S-4，拟将注册地从瑞士迁至特拉华州，并更名为 ADC Therapeutics, Inc.。","reason","source",{"_11":88,"_89":90,"_91":92,"_93":57,"_94":95,"_96":97},"links",{"_85":86,"_63":87},"publishedAt","2026-11-03T22:02:54.000Z","discoveredAt","2026-11-04T00:50:01.705Z","timelineAt","category","tip","tags",[81,82,83,84],"stockSymbols",[80],"score",36,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fhpGDnP0PdPg",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","ef1c6577-bd3e-407a-ae91-138aa6d5e0d3","ADC Therapeutics拟迁册特拉华州并更名",{"_72":73,"_15":74},"zh","

As filed with the Securities and Exchange Commission\non November 3, 2026.

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-4

REGISTRATION STATEMENT UNDER THE SECURITIES ACT\nOF 1933

ADC THERAPEUTICS SA*

(Exact name of Registrant as specified in its charter)

\n \n \n \n \n \n \n \n \n

Switzerland*	2834	Not Applicable
(State or other jurisdiction of incorporation or organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification No.)

Biopôle

Route de la Corniche 3B

1066 Epalinges

Switzerland

+41 21 653 02 00*

(Address, including zip code, and telephone number,\nincluding area code, of Registrant’s principal executive offices)

ADC Therapeutics America, Inc.

430 Mountain Avenue, 4^th Floor

New Providence, New Jersey 07974

(908) 731-5556

(Name, address, including zip code, and telephone\nnumber, including area code, of agent for service)

Copies to:

\n \n \n \n \n

Yasin Keshvargar
\nDavid (Wei Fu) Li
\nDavis Polk & Wardwell LLP
\n450 Lexington Avenue
\nNew York, NY 10017
\n(212) 450-4000

Dieter Gericke
\nDaniel Häusermann
\nHomburger AG
\nHardstrasse 201
\nCH-8005 Zurich, Switzerland
\n+41 43 222 10 00

Approximate date of commencement of proposed sale of the securities\nto the public: As soon as practicable after this registration statement becomes effective and all other conditions to the Redomiciliation\nTransaction described in the proxy statement/prospectus included in this registration statement have been satisfied.

If the securities being registered on this Form are being offered in\nconnection with the formation of a holding company and there is compliance with General Instruction G, check the following box. ☐

If this Form is filed to register additional securities for an offering\npursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of\nthe earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d)\nunder the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective\nregistration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated\nfiler, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of\n“large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth\ncompany” in Rule 12b-2 of the Exchange Act.

\n \n \n \n \n \n \n \n \n \n

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the\nregistrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

If applicable, place an X in the box to designate the appropriate rule\nprovision relied upon in conducting this transaction:

Exchange Act Rule 13e-4(i) (Cross-Border Issuer\nTender Offer) ☐

Exchange Act Rule 14d-1(d) (Cross-Border Third-Party\nTender Offer) ☐

* Following the effectiveness of this registration statement, ADC Therapeutics\nSA intends, subject to the approval of ADC Therapeutics SA’s shareholders and satisfaction of all other conditions to the Redomiciliation\nTransaction described in the proxy statement/prospectus included in this registration statement, to become a corporation incorporated\nunder the laws of the State of Delaware under the name ADC Therapeutics, Inc., with principal executive offices at 430 Mountain Avenue,\n4th Floor, New Providence, NJ 07974, and telephone number of (908) 731-5556.

The registrant hereby amends this registration statement on such\ndate or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states\nthat this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act or until this\nregistration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section\n8(a), may determine.

Ron Squarer	Peter J. Graham
Chair of the board of directors	Secretary

ABOUT THIS PROXY STATEMENT/PROSPECTUS	1
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS	2
QUESTIONS AND ANSWERS	4
PROXY STATEMENT/PROSPECTUS SUMMARY	14
RISK FACTORS	19
THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS	24
PROPOSAL 1: THE REDOMICILIATION PROPOSAL	27
PROPOSAL 2: THE CONSTITUTIVE DOCUMENTS PROPOSAL	33
PROPOSAL 3: THE DISCHARGE PROPOSAL	46
SHARE INFORMATION	47
MANAGEMENT AND EXECUTIVE AND DIRECTOR COMPENSATION	48
CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS	49
MATERIAL TAX CONSIDERATIONS	51
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT	64
INFORMATION INCORPORATED BY REFERENCE	66
LEGAL MATTERS	67
EXPERTS	67
OTHER MATTERS	68
ANNEX A: FORM OF CERTIFICATE OF CORPORATE DOMESTICATION	69
ANNEX B: PROPOSED CERTIFICATE OF INCORPORATION	70
ANNEX C: PROPOSED BYLAWS	76
ANNEX D: FORM OF PROXY CARD	90

	ADC Therapeutics, Inc. \n(Delaware)	ADC Therapeutics SA \n(Switzerland)
*Capital Stock / Share Capital*
Authorized Capital	We have 394,000,000 shares of authorized common stock and 3,000,000 shares of authorized preferred stock. The board of directors is authorized to issue shares out of authorized capital stock from time to time without further action or vote from stockholders, subject to applicable stock exchange rules and the certificate of incorporation.	We have a capital range ranging from CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit). In addition, our share capital may be increased by up to CHF 1,346,900.24 through the issuance of up to 16,836,253 common shares for equity-based compensation purposes and by up to CHF 3,842,154.32 through the issuance of up to 48,026,929 common shares for financing and acquisition purposes. The board of directors is authorized to issue shares out of the capital range or conditional share capital from time to time without further action or vote from shareholders, subject to applicable stock exchange rules and the articles of association.

Preferred Stock	The board of directors may authorize, without further action or vote from stockholders, subject to applicable stock exchange rules and the certificate of incorporation, one or more series of preferred stock and fix such series’ designations, powers, preferences, rights, qualifications, limitations and restrictions thereof, if any, and the number of shares constituting such series.	The articles of association do not contemplate preferred shares. Shareholders can authorize the board of directors to issue, subject to the articles of association, preferred shares and fix such preferred shares’ dividend, liquidation or other preferences. Shareholders can also authorize the board of directors to issue, subject to the articles of association, shares with up to ten times more voting power than common shares.
*Rights of Common Stock / Common Shares*
Voting Rights	Holders of common stock are entitled to one vote per share held of record by such holder on all matters on which stockholders generally are entitled to vote.	Holders of common shares are entitled to one vote per share held of record by such holder on all matters on which shareholders generally are entitled to vote. However, no person will be registered in the share register as a shareholder with voting rights with respect to more than 15% of share capital.

Conversion Rights	Common stock is not convertible into any other security.	Common shares are not convertible into any other security.
Redemption Rights	Common stock is not redeemable by us or at the option of its holders.	Common shares are not redeemable by us or at the option of their holders.
Sinking Fund Provisions	There are no sinking fund provisions applicable to the common stock.	There are no sinking fund provisions applicable to the common shares.
*Board of Directors*
Board Size	The number of directors constituting the board of directors is between three and nine, with the exact number determined from time to time exclusively by the directors then in office.	The number of directors constituting the board of directors is between three and nine. The board of directors cannot change its size without shareholder approval.
Election Frequency	From and after the Classification Time, directors are divided into three classes, serving staggered three-year terms.	Directors are elected annually.
Election Standard	Directors are elected by plurality of the votes cast (i.e., nominees with the highest number of “for” votes are elected).	Directors are elected by a majority of the votes represented (i.e., nominees with more “for” votes than “against” and “abstain” votes are elected).
Cumulative Voting	There is no cumulative voting in the election of directors.	There is no cumulative voting in the election of directors.
Filling Vacancies	Vacancies on the board of directors are filled only by the board of directors and not by stockholders.	Vacancies on the board of directors are filled only by shareholders and not the board of directors.
Removal	Prior to the Classification Time, directors can be removed by stockholders only with the affirmative vote of the holders of not less than 66⅔% of the voting power of all outstanding shares entitled to vote generally in the election of directors, voting together as a single class. From and after the Classification Time, directors can be removed by stockholders only for cause with the affirmative vote of the holders of not less than 66⅔% of the voting power of all outstanding shares entitled to vote generally in the election of directors, voting together as a single class.	Directors can be removed by shareholders only with the affirmative vote of 66⅔% of the votes represented and the majority of the par value of shares represented at a shareholders meeting.
Fiduciary Duties	\n A director of a Delaware corporation has a fiduciary duty ‎to the\n corporation and its stockholders. This duty has two ‎components:‎ \n \n · \n the duty of care; and \n \n · \n the duty of loyalty.‎ \n \n The duty of care requires that a director act in good faith, ‎with\n the care that an ordinarily prudent person would ‎exercise under similar circumstances. Under this duty, a ‎director must inform\n himself or herself of, and disclose to ‎stockholders, all material information reasonably ‎available regarding a significant transaction.‎ \n \n The duty of loyalty requires that a director act in a ‎manner\nhe or she reasonably believes to be in the best ‎interests of the corporation. He or she must not use his or ‎her corporate position\nfor personal gain or advantage. ‎This duty prohibits self-dealing by a director and ‎mandates that the best interest of the corporation\nand its ‎stockholders take precedence over any interest possessed ‎by a director, officer or controlling stockholder and not\n‎shared by the stockholders generally. In general, actions ‎of a director are presumed to have been made on an ‎informed\nbasis, in good faith and in the honest belief that ‎the action taken was in the best interests of the ‎corporation. However,\nthis presumption may be rebutted ‎by evidence of a breach of one of the fiduciary duties.	\n The board of directors of a Swiss corporation manages ‎the business\n of the corporation, unless responsibility for ‎such management has been duly delegated to the ‎executive committee based on organizational\n rules. ‎However, there are several nontransferable duties of ‎the board of directors:‎ \n \n · ‎the overall management of the corporation and ‎the issuing of all necessary directives;‎ \n \n · determination of the corporation’s organization;‎ \n \n · the organization of the accounting, ‎financial control and financial planning systems as ‎required for management of ‎the\n corporation;‎ \n \n · the appointment and dismissal of persons ‎entrusted with managing and representing the ‎corporation;‎ \n \n · overall supervision of the persons entrusted with ‎managing the corporation, in particular with regard ‎to compliance ‎with\n the law, articles of association, ‎operational regulations and directives;‎ \n

	Should such evidence be presented concerning a ‎transaction by a director, a director must prove the ‎procedural fairness of the transaction and that the ‎transaction was of fair value to the corporation.‎	\n · compilation of the annual report, preparation for ‎the general meeting of the shareholders, the ‎compensation report ‎and\n implementation of its ‎resolutions; and \n \n · the filing of an application for a debt restructuring moratorium and notification of the court in the event that the ‎company is over-indebted.‎ \n \n The members of the board of directors must perform ‎their duties\n with all due diligence and safeguard the ‎interests of the corporation in good faith. They must ‎afford the shareholders equal\n treatment in equal ‎circumstances. \n \n ‎The duty of care requires that a director act in good ‎faith,\n with the care that an ordinarily prudent director ‎would exercise under like circumstances. \n \n The members of the board of directors and the executive committee are\n required to immediately and fully inform the board of directors about conflicts of interests concerning them. The board of directors is\n furthermore required to take measures in order to protect the interests of the company. \n \n The duty of loyalty requires that a director safeguard ‎the interests\n of the corporation and requires that ‎directors act in the interest of the corporation and, if ‎necessary, put aside their own\n interests. If there is a risk ‎of a conflict of interest, the board of directors must ‎take appropriate measures to ensure that\n the interests ‎of the company are duly taken into account.‎ \n \n The burden of proof for a violation of these duties is ‎with the\n corporation or with the shareholder bringing a ‎suit against the director.‎ \n \n The Swiss Federal Supreme Court has established a doctrine that restricts\n its review of a business decision if the decision has been taken following proper preparation, on an informed basis and without conflicts\n of interest. \n
*Shareholder Actions*
Special Meetings	Special meetings can be called only by the board of directors or by the Chief Executive Officer. Stockholders cannot call special meetings	Shareholders who, alone or together, hold at least 5% of share capital may request the board of directors to call special meetings.
Written Consent	Stockholders cannot act by written consent. Stockholder action can only be taken at a stockholder meeting.	Shareholders can act by written consent only if no shareholder requests a meeting. Otherwise, shareholder action can only be taken at a shareholder meeting.
Shareholder Proposals	A stockholder of a Delaware corporation has the right to ‎put any proposal before the annual meeting of ‎stockholders, provided it complies with the advanced notice ‎provisions in the bylaws. Stockholders do not have proxy access rights.	Shareholders who, alone or together, hold at least 0.5% of share capital may request that an item be included on the agenda for a shareholders meeting, provided that the request complies with the advanced notice provisions in the articles of association.

*Exculpation and Indemnification for Directors and Officers*
Exculpation	\n To the fullest extent permitted by the DGCL, no director or officer\n is personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director or officer. \n \n Currently, the DGCL requires that liability be imposed for the following: \n \n ·\t a\n director’s or officer’s breach of the director’s or officer’s duty of loyalty to us or our stockholders; \n \n ·\t a\n director’s or officer’s act or omission not in good faith or which involved intentional misconduct or a knowing violation\n of law; \n \n ·\t a\n director’s unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; \n \n ·\t a\n director or officer for any transaction from which the director or officer derived an improper personal benefit; and \n \n ·\t an\nofficer in any action by or in the right of us.	The general meeting of ‎shareholders may discharge (i.e., release) the directors and ‎members of the executive committee from liability for ‎their conduct to the extent the respective facts are ‎known to shareholders. Such discharge is effective only ‎with respect to claims of the company and of those ‎shareholders who approved the discharge or who have ‎since acquired their shares in full knowledge of the ‎discharge. Most violations of corporate law are ‎regarded as violations of duties towards the corporation ‎rather than towards the shareholders.‎
Indemnification	To the fullest extent permitted by the DGCL, we indemnify each person (and the heirs, executors or administrators of such person) who was or is a party or is threatened to be made a party to, or is involved in any threatened, pending or completed action, suit or proceeding by reason of the fact that such person is or was our director or officer or, while a director or officer, is or was serving at our request as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding.	Subject to Swiss law, we indemnify existing and former members of our board of directors and our executive committee as well as their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity.
*Dispute Resolution*
Exclusive Forum	The exclusive forum for substantially all disputes between us and our stockholders (other than claims under the Securities Act and the Exchange Act) is the Court of Chancery of the State of Delaware. The exclusive forum for claims under the Securities Act is the federal district courts of the United States.	The exclusive place of jurisdiction for substantially all disputes between us and our shareholders or directors based on corporation law (other than claims under the Securities Act and the Exchange Act) is Epalinges, Canton of Vaud, Switzerland.
Class Actions and Derivative Actions	Class actions and derivative actions generally are ‎available to stockholders of a Delaware corporation for, ‎among other things, breach of fiduciary duty, corporate ‎waste and actions not taken in accordance with ‎applicable law. In such actions, the court has discretion to ‎permit the winning party to recover attorneys’ fees ‎incurred in connection with such action.‎	‎Class actions and derivative actions as such are not ‎available under Swiss law. Nevertheless, certain actions ‎may have a similar effect. A shareholder is entitled to ‎bring suit against directors, officers or liquidators for ‎breach of their duties and claim the payment of the ‎company’s losses or damages to the corporation and, ‎in some cases, to the individual shareholder. Likewise, ‎an appraisal lawsuit won by a shareholder may ‎indirectly compensate all shareholders.

Dissolution and Winding Up	\n If the board of directors ‎does not approve the proposal to dissolve,\n dissolution must be ‎approved by stockholders holding 100% of the voting power of all outstanding securities. \n \n If the board of directors initiates the proposal to dissolve, dissolution\nmust be approved by a majority of the voting power of all outstanding securities.	Dissolution requires the ‎approval by 66⅔% of the votes represented and the majority of the par value of shares represented at a shareholders meeting.
*Executive and Director Compensation‎*
Compensation Determinations	Under the DGCL, unless otherwise restricted by the certificate of ‎incorporation or bylaws, the board ‎of directors has the authority to fix the compensation of ‎directors and officers.‎	Pursuant to our articles of association, the general meeting of ‎shareholders has the nontransferable right to vote separately and bindingly on the ‎aggregate maximum amount of compensation of the members of ‎the board of directors, the aggregate maximum amount of the fixed compensation of the executive committee and ‎of aggregate maximum amount of variable compensation of the executive committee.‎
Compensation Committee	Members of the compensation committee are appointed by the board of directors. The board of directors may remove members of the compensation committee.	Members of the compensation committee are elected by shareholders annually. Only shareholders may remove members of the compensation committee.
*Inspection of Books and Records*
Inspection Rights	Stockholders of a Delaware corporation, upon written ‎demand under oath stating the purpose thereof, have the ‎right during the usual hours for business to inspect for any ‎proper purpose, and to obtain copies of list(s) of ‎stockholders and other books and records of the ‎corporation and its subsidiaries, if any, to the extent the ‎books and records of such subsidiaries are available to ‎the corporation.	Shareholders of a Swiss corporation holding in the aggregate at least 5% of the nominal share capital or voting rights have the right to inspect ‎books and records, subject to the safeguarding of the company’s business secrets and other interests warranting protection. A ‎shareholder is only entitled to receive information to ‎the extent required to exercise his or her rights as a ‎shareholder. A shareholder’s right to inspect the share register is ‎limited to the right to inspect his or her own entry in the ‎share register.

Name	Position(s)
Executive Officers and Directors
Ameet Mallik	Chief Executive Officer and Director
Jose “Pepe” Carmona	Chief Financial Officer
Peter Graham	Chief Legal and Compliance Officer
Mohamed Zaki	Chief Medical Officer
Non-Executive Directors
Ron Squarer	Chair of the Board of Directors
Peter Hug	Vice Chair of the Board of Directors and Lead Independent Director
Robert Azelby	Director
Jean-Pierre Bizzari	Director
Timothy Coughlin	Director
Viviane Monges	Director
Tyrell J. Rivers	Director
Victor Sandor	Director

Principal Shareholders	Number of Common Shares Beneficially Owned	Percentage of Common Shares Beneficially Owned
Directors and Executive Officers
Robert Azelby		*
Jean-Pierre Bizzari		*
Jose “Pepe” Carmona		*
Timothy Coughlin		*
Peter Graham		*
Peter Hug		*
Ameet Mallik		%
Viviane Monges		*
Tyrell J. Rivers (1)		*
Victor Sandor		*
Ron Squarer		%
Mohamed Zaki		*
Directors and executive officers as a group (12 persons)		%
5% Shareholders
(2)		%
(3)		%
(4)		%
(5)		%
(6)		%
(7)		%

ADC Therapeutics SA


By:
	Name:\tAmeet Mallik
	Title:\tChief Executive Officer

\n ADC Therapeutics, Inc. \n

By:
	Name:\tAmeet Mallik
	Title:\tChief Executive Officer

		Incorporation by Reference
Exhibit No.	Description	Form	File No.	Exhibit No.	Filing Date
2.1	Form of Certificate of Corporate Domestication (included as Annex A to the proxy statement/prospectus which forms a part of this\n registration statement)
3.1	Articles of Association of ADC Therapeutics SA	8-K	001-39071	3.1	June 2, 2026
3.2	Form of Certificate of Incorporation of ADC Therapeutics, Inc. (included as Annex B to the proxy statement/prospectus which forms\n a part of this registration statement)
3.3	Form of Bylaws of ADC Therapeutics, Inc. (included as Annex C to the proxy statement/prospectus which forms a part of this registration statement)
5.1*	Opinion of Davis Polk & Wardwell LLP regarding the validity of ADC Therapeutics, Inc.’s shares of common stock
8.1*	Opinion of Davis Polk & Wardwell LLP regarding certain U.S. federal income tax matters
8.2*	Opinion of Homburger AG regarding certain Swiss tax matters
23.1	Consent of PricewaterhouseCoopers SA
23.2*	Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)
23.3*	Consent of Davis Polk & Wardwell LLP (included in Exhibit 8.1)
23.4*	Consent of Homburger AG (included in Exhibit 8.2)
24.1	Powers of attorney (included on signature page of this registration statement)
99.1*	Form of proxy card (included as Annex D to the proxy statement/prospectus which forms a part of this registration statement)
107	Filing fee table

ADC THERAPEUTICS SA

By:	/s/ Ameet Mallik
	Name:	Ameet Mallik
	Title:	Chief Executive Officer

Name		Title

/s/ Ameet Mallik		\n Chief Executive Officer and Director \n (principal executive officer)
Ameet Mallik

/s/ Jose “Pepe” Carmona		\n Chief Financial Officer \n (principal financial officer)
Jose “Pepe” Carmona

/s/ Lisa Kallebo		\n Corporate Controller and Chief Accounting Officer \n (principal accounting officer)
Lisa Kallebo

/s/ Ron Squarer		Chair of the Board of Directors
Ron Squarer

/s/ Peter Hug		Vice Chair of the Board of Directors and Lead Independent Director
Peter Hug

/s/ Robert Azelby		Director
Robert Azelby

/s/ Jean-Pierre Bizzari		Director
Jean-Pierre Bizzari

/s/ Timothy Coughlin		Director
Timothy Coughlin

/s/ Viviane Monges		Director
Viviane Monges

/s/ Tyrell J. Rivers		Director
Tyrell J. Rivers

/s/ Victor Sandor		Director
Victor Sandor

/s/ Jose “Pepe” Carmona		Authorized Representative in the United States
Jose “Pepe” Carmona
ADC Therapeutics America, Inc.